Breaking Boundaries

Engineering the Future Of Targeted Medicines
We are focused on developing
Next- Generation
therapeutics to specifically target difficult-to-treat medical conditions for the benefit of patients

VBL is a Phase 3 biotechnology company using the molecular machinery of the body to precisely address disease. Our proprietary gene-targeting and antibody technologies were designed to provide

Exquisite Solutions
For People with Cancer and Immune-Inflammatory Diseases

Our expertise in human biology led to the development of our proprietary gene targeting and antibody platform technologies, which are designed to precisely address advanced cancers and immune-inflammatory diseases. Our lead oncology candidate, ofra-vec, is currently being evaluated in our OVAL Phase 3 registration-enabling clinical trial in ovarian cancer.